A current working hypothesis is that by inhibiting the enzyme activity of 17β-HSD10 (a contributor to the β-fatty acid oxidation pathway) this can help re-balance alterations in glucose metabolism observed in AD (Aitken unpublished data). This evidence concerns the gene HSD17B10 and Alzheimer disease.